Copyright
©The Author(s) 2023.
World J Clin Cases. Jul 16, 2023; 11(20): 4740-4751
Published online Jul 16, 2023. doi: 10.12998/wjcc.v11.i20.4740
Published online Jul 16, 2023. doi: 10.12998/wjcc.v11.i20.4740
Ref. | Patient characteristics | Type of eradication therapy | Type of probiotic | Results |
Çekin et al[54], 2017 | 159 patients with H. pylori infection | 14-d sequential H. pylori eradication therapy | Bifidobacterium animalis subsp. lactis B94 1 capsule/d | (1) Eradication rates in the probiotic group/placebo group were 86.8% vs 70.8%, P = 0.025; (2) Lower first week diarrhea; and (3) Less common self-reported side effects and higher treatment compliance |
Dajani et al[55], 2013 | 377 patients | Standard triple therapy, sequential treatment | Bifidus infantis 2036 at 30 × 108 colony-forming units twice daily | Eradication rate: Standard therapy-68.9%, probiotic with triple therapy- 83%, pre-treatment before triple therapy-90.5%, probiotic with sequential therapy-90.8% (P < 0.05) |
- Citation: Baryshnikova NV, Ilina AS, Ermolenko EI, Uspenskiy YP, Suvorov AN. Probiotics and autoprobiotics for treatment of Helicobacter pylori infection. World J Clin Cases 2023; 11(20): 4740-4751
- URL: https://www.wjgnet.com/2307-8960/full/v11/i20/4740.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v11.i20.4740